Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tivity Health (TVTY), Ionis Pharmaceuticals (IONS) and Xencor (XNCR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tivity Health (TVTYResearch Report), Ionis Pharmaceuticals (IONSResearch Report) and Xencor (XNCRResearch Report).

Tivity Health (TVTY)

Barrington analyst Michael Petusky maintained a Hold rating on Tivity Health today. The company’s shares closed last Friday at $32.03, close to its 52-week high of $32.89.

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 7.9% and a 48.9% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, ATI Physical Therapy, and US Physical Therapy.

Tivity Health has an analyst consensus of Hold, with a price target consensus of $31.75.

See the top stocks recommended by analysts >>

Ionis Pharmaceuticals (IONS)

BMO Capital analyst Gary Nachman reiterated a Buy rating on Ionis Pharmaceuticals today and set a price target of $70.00. The company’s shares closed last Friday at $36.49.

According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of -7.9% and a 38.9% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Phathom Pharmaceuticals, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $52.54 average price target, representing a 40.9% upside. In a report issued on April 29, Piper Sandler also maintained a Buy rating on the stock with a $54.00 price target.

Xencor (XNCR)

In a report released today, Etzer Darout from BMO Capital maintained a Buy rating on Xencor, with a price target of $50.00. The company’s shares closed last Friday at $24.90, close to its 52-week low of $24.30.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 39.4% and a 43.5% success rate. Darout covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Fate Therapeutics, and C4 Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xencor with a $50.86 average price target, representing a 91.9% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $56.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TVTY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More